[1]. A comparison of two types of contrast media used in endoscopic retrograde cholangiopancreatography: A retrospective study.
PloS one [巻]18 [号]1 [頁]e0280279 （2023年）
[DOI] [2]. Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study.
Medicine [巻]101 [号]40 [頁]e31017 （2022年）
[DOI] [3]. Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study.
BMC gastroenterology [巻]22 [号]1 [頁]420 （2022年）
[DOI] [4]. Modified method of patency judgement using patency capsule prior to capsule endoscopy in clinical practice.
Scientific reports [巻]12 [号]1 [頁]14335 （2022年）
[DOI] [5]. Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis.
Scientific reports [巻]12 [号]1 [頁]13572 （2022年）
[DOI] [6]. Predicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite.
Clinical and translational gastroenterology [巻]13 [号]7 [頁]e00501 （2022年）
[DOI] [7]. Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel : Influence of alternate-day dosing of vonoprazan.
European journal of clinical pharmacology （2022年） [査読] 有
[DOI] [機関リポジトリ][8]. Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy.
Gastroenterology report [巻]10 [頁]goac025 （2022年）
[DOI] [9]. Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse.
International journal of colorectal disease [巻]36 [号]12 [頁]2661 -2670 （2021年）
[DOI] [10]. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis.
Digestive diseases and sciences （2021年）
[DOI] [11]. Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis.
Scientific reports [巻]11 [号]1 [頁]16205 （2021年）
[DOI] [12]. Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission.
Medicine [巻]100 [号]29 [頁]e26550 （2021年）
[DOI] [13]. Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia.
European journal of clinical pharmacology [巻]77 [号]7 [頁]971 -978 （2021年）
[DOI] [14]. Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis.
Scientific reports [巻]11 [号]1 [頁]13676 （2021年）
[DOI] [15]. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome.
World journal of gastroenterology [巻]27 [号]22 [頁]3109 -3120 （2021年）
[DOI] [16]. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis.
Scientific reports [巻]11 [号]1 [頁]12431 （2021年）
[DOI] [17]. Evaluation of the modified Crohn's disease activity index in patients with Crohn disease with enterostomy: A single-center observational study.
Medicine [巻]100 [号]6 [頁]e24717 （2021年）
[DOI] [18]. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
PloS one [巻]16 [号]7 [頁]e0254548 （2021年）
[DOI] [19]. Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease.
PloS one [巻]16 [号]4 [頁]e0250658 （2021年）
[DOI] [20]. Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: A case report.
World journal of gastroenterology [巻]26 [号]45 [頁]7263 -7271 （2020年）
[DOI] [21]. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation.
Scientific reports [巻]10 [号]1 [頁]21353 （2020年）
[DOI] [22]. Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission.
Clinical and translational gastroenterology [巻]11 [号]12 [頁]e00289 （2020年）
[DOI] [23]. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy.
BMC cancer [巻]20 [号]1 [頁]1123 （2020年）
[DOI] [24]. Influence of clarithromycin on the bactericidal effect of amoxicillin in patients infected with clarithromycin-resistant strains of .
Gut [巻]69 [号]11 [頁]2056 （2020年） [査読] 有
[DOI] [機関リポジトリ][25]. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker.
International journal of colorectal disease [巻]35 [号]9 [頁]1729 -1739 （2020年）
[DOI] [26]. DNA mismatch repair is not disrupted in stage 0 colorectal cancer resected using endoscopic submucosal dissection.
Oncology letters [巻]20 [号]3 [頁]2435 -2441 （2020年）
[DOI] [27]. Microsatellite frameshift variants in of gastric cancer are not always associated with MSI status.
Journal of clinical pathology （2020年）
[DOI] [28]. Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation.
Inflammatory bowel diseases （2020年）
[DOI] [29]. The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study.
Medicine [巻]99 [号]29 [頁]e21226 （2020年）
[DOI] [30]. A rectal neuroendocrine tumor in a patient with Crohn's disease: a case report and literature review.
Clinical journal of gastroenterology [巻]13 [号]3 [頁]320 -327 （2020年）
[DOI] [31]. Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience.
Journal of clinical medicine [巻]9 [号]5 （2020年）
[DOI] [32]. Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis.
BMC gastroenterology [巻]20 [号]1 [頁]114 （2020年）
[DOI] [33]. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study).
Alimentary pharmacology & therapeutics [巻]51 [号]5 [頁]534 -543 （2020年）
[DOI] [34]. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
Digestion [巻]101 [号]6 [頁]743 -751 （2020年）
[DOI] [35]. Decompressive laparotomy for abdominal compartment syndrome resulting from severe acute pancreatitis: a case report.
BMC gastroenterology [巻]19 [号]1 [頁]141 （2019年）
[DOI] [36]. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.
iScience [巻]10 [頁]247 -264 （2018年）
[DOI] [37]. Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission.
World journal of clinical cases [巻]6 [号]15 [頁]952 -960 （2018年）
[DOI] [38]. High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy.
Oncotarget [巻]9 [号]79 [頁]34876 -34888 （2018年）
[DOI] [39]. Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.
Clinical pharmacology and therapeutics [巻]103 [号]5 [頁]906 -913 （2018年）
[DOI] [40]. Prevalence of elevated microsatellite alterations at selected tetranucleotide repeats in pancreatic ductal adenocarcinoma.
PloS one [巻]13 [号]12 [頁]e0208557 （2018年）
[DOI] [41]. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.
European journal of clinical pharmacology [巻]74 [号]1 [頁]45 -52 （2018年）
[DOI] [42]. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.
Journal of thrombosis and thrombolysis [巻]43 [号]3 [頁]333 -342 （2017年）
[DOI] [43]. One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.
European journal of clinical pharmacology [巻]71 [号]12 [頁]1467 -75 （2015年）
[DOI] [44]. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research [巻]21 [号]18 [頁]4184 -93 （2015年） [査読] 有
[DOI] [45]. Influence of prostate stem cell antigen gene polymorphisms on susceptibility to Helicobacter pylori-associated diseases: a case-control study.
Helicobacter [巻]20 [号]2 [頁]106 -13 （2015年）
[DOI] [46]. Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg.
Digestion [巻]91 [号]4 [頁]277 -85 （2015年）
[DOI] [47]. Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison.
Journal of clinical biochemistry and nutrition [巻]55 [号]3 [頁]178 -83 （2014年）
[DOI] [48]. Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
Journal of clinical pharmacology [巻]54 [号]8 [頁]858 -64 （2014年）
[DOI] [49]. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
Helicobacter [巻]19 [号]4 [頁]312 -8 （2014年）
[DOI] [50]. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
Journal of gastroenterology and hepatology [巻]29 [号]3 [頁]487 -93 （2014年）
[DOI] [51]. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy.
Journal of clinical pharmacology [巻]54 [号]3 [頁]258 -66 （2014年）
[DOI] [52]. Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin.
Internal medicine (Tokyo, Japan) [巻]53 [号]6 [頁]571 -5 （2014年）
[DOI] [53]. [Judgment of eradication of H. pylori based on percent changes in serum pepsinogens].
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology [巻]110 [号]2 [頁]210 -7 （2013年）
[54]. Association of gastric mucosal injury severity with platelet function and gastric pH during low-dose aspirin treatment.
Digestion [巻]88 [号]2 [頁]79 -86 （2013年）
[DOI] [55]. Antiplatelet drugs are a risk factor for esophageal mucosal injury.
Digestion [巻]87 [号]4 [頁]281 -9 （2013年）
[DOI] [56]. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [巻]10 [号]8 [頁]879 -885.e2 （2012年）
[DOI] [57]. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.
Journal of clinical pharmacology [巻]52 [号]3 [頁]432 -9 （2012年）
[DOI] [58]. Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Digestion [巻]85 [号]1 [頁]9 -17 （2012年）
[DOI] [59]. Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence.
Anticancer research [巻]32 [号]1 [頁]105 -14 （2012年） [査読] 有
[60]. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan.
Journal of gastroenterology and hepatology [巻]26 [号]9 [頁]1457 -61 （2011年） [査読] 有
[DOI] [61]. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.
Journal of clinical pharmacology [巻]51 [号]7 [頁]1079 -86 （2011年）
[DOI] [62]. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.
World journal of gastroenterology [巻]17 [号]14 [頁]1858 -65 （2011年）
[DOI] [63]. [A case of eosinophilic gastroenteritis accompanied with fasciitis of the extremities].
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology [巻]108 [号]3 [頁]444 -50 （2011年）
[64]. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.
Digestive diseases and sciences [巻]55 [号]6 [頁]1627 -36 （2010年）
[DOI] [65]. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
Journal of clinical pharmacology [巻]50 [号]3 [頁]320 -30 （2010年）
[DOI] [66]. The Dual Therapy with 4 Times Daily Dosing of Rabeprazole and Amoxicillin as the 3(rd) Rescue Regimen for Eradication of H. pylori
HEPATO-GASTROENTEROLOGY [巻]57 [号]102-03 [頁]1314 -1319 （2010年）
[67]. Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.
BMC cancer [巻]9 [頁]408 （2009年）
[DOI] [68]. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.
European journal of clinical pharmacology [巻]65 [号]7 [頁]693 -8 （2009年）
[DOI] [69]. Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects.
European journal of clinical pharmacology [巻]65 [号]6 [頁]593 -600 （2009年）
[DOI] [70]. MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese.
Life sciences [巻]83 [号]7-8 [頁]301 -4 （2008年）
[DOI] [71]. Polymorphisms of matrix metalloproteinase-7 and chymase are associated with susceptibility to and progression of gastric cancer in Japan.
Journal of gastroenterology [巻]43 [号]10 [頁]751 -61 （2008年）
[DOI] [72]. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.
Expert opinion on pharmacotherapy [巻]8 [号]16 [頁]2701 -17 （2007年）
[DOI] [73]. Personalized medicine for eradication of Helicobacter pylori.
Personalized medicine [巻]4 [号]3 [頁]321 -328 （2007年）
[DOI]